Go Deep
Aura Biosciences, Inc.
Aura Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,722 | -3.6 | 2.06 | 0.05 | 597.12 |
| Oct 2026 | 19,791 | -3.5 | 2.03 | 0.05 | 585.83 |
| Oct 2026 | 19,674 | -3.7 | 2.08 | 0.05 | 602.05 |
| Oct 2026 | 19,839 | -3.5 | 2.01 | 0.05 | 577.76 |
| Oct 2026 | 19,708 | -3.6 | 2.07 | 0.05 | 596.40 |
| Oct 2026 | 19,522 | -3.7 | 2.16 | 0.05 | 622.00 |
| Oct 2026 | 19,591 | -3.7 | 2.12 | 0.05 | 611.00 |
| Oct 2026 | 19,591 | -3.7 | 2.12 | 0.05 | 609.76 |
Aura Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -45,637,000.0 | -33,685,000.0 | -25,559,000.0 | -26,130,000.0 |
| EPS | -0.5 | -0.5 | — | -0.4 |
Aura Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -106,191,000.0 | -86,919,000.0 | -76,408,000.0 | -58,763,000.0 | — |
| EPS | -1.8 | -1.8 | -1.9 | -2.0 | — |
Aura Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 169,430,000.0 | 182,503,000.0 | 255,075,000.0 | 223,935,000.0 | — |
| Total Liabilities | 32,517,000.0 | 30,533,000.0 | 29,227,000.0 | 28,352,000.0 | — |
| Total Equity | 136,913,000.0 | 151,970,000.0 | 225,848,000.0 | 195,583,000.0 | — |
Owes vs Owns
Aura Biosciences, Inc. owed $0.09 for every $1 it owned in Jun 2026, down from $0.13 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.09× | 0.19× | 0.17× | 0.11× | 0.13× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aura Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 85.1%Fixed assets (tangible) 10.9%Other assets 4.0%
How it's funded — Dec 2025
Short-term debt 1.9%Long-term debt 8.3%Payables 0.9%Other liabilities 8.0%Shareholders' equity 80.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 144.2 | 151.1 | 226.2 | 188.8 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 18.5 | 20.6 | 22.0 | 26.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 6.7 | 10.8 | 6.9 | 9.1 |
| Liabilities & equity | ||||
| Short-term debt | 3.2 | 3.1 | 2.7 | 3.0 |
| Long-term debt | 14.1 | 15.6 | 16.9 | 17.9 |
| Payables | 1.5 | 2.3 | 1.8 | 2.9 |
| Other liabilities | 13.6 | 9.5 | 7.9 | 4.6 |
| Shareholders' equity | 136.9 | 152.0 | 225.8 | 195.6 |
| Net tangible assets | 136.9 | 152.0 | 225.8 | 195.6 |
Aura Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -84,742,000.0 | -79,805,000.0 | -63,847,000.0 | -54,601,000.0 | — |
| Investing Activities | 35,595,000.0 | 68,821,000.0 | -113,963,000.0 | -67,869,000.0 | — |
| Financing Activities | 77,155,000.0 | 1,595,000.0 | 97,290,000.0 | 95,629,000.0 | — |